COMBINATIONS OF LOW, IMMUNE ENHANCING, DOSES OF MTOR INHIBITORS AND CARS

• US 20170274014A1
• Filed: 07/21/2014
• Published: 09/28/2017
• Est. Priority Date: 07/21/2014
• Status: Abandoned Application

• Current Assignee: David Glass, Jennifer Brogdon, Joan Mannick, Leon C. Murphy, Michael C. Milone
• Original Assignee: David Glass, Jennifer Brogdon, Joan Mannick, Leon C. Murphy, Michael C. Milone
• Inventors: Brogdon, Jennifer, Glass, David, Mannick, Joan, Milone, Michael C., Murphy, Leon
• Application Number:
  US15/327,758
• Publication Number:
  US 20170274014A1
• Time in Patent Office: Days
• CPC Class Codes: A61K 2039/505 comprising antibodies
• CPC Class Codes: A61K 2039/55 characterised by the host/recipient, e.g. newborn with maternal antibodies
• CPC Class Codes: A61K 2039/55511 Organic adjuvants
• CPC Class Codes: A61K 2039/70 Multivalent vaccine
• CPC Class Codes: A61K 2239/31 characterized by the route of administration
• CPC Class Codes: A61K 2239/38 characterised by the dose, timing or administration schedule
• CPC Class Codes: A61K 2239/48 Blood cells, e.g. leukemia or lymphoma
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 31/436 the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
• CPC Class Codes: A61K 35/17 Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes when activated by a specific antigen A61K39/00
• CPC Class Codes: A61K 39/12 Viral antigens
• CPC Class Codes: A61K 39/3955 against proteinaceous materials, e.g. enzymes, hormones, lymphokines
• CPC Class Codes: A61K 39/39558 against tumor tissues, cells, antigens
• CPC Class Codes: A61K 39/4611 T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
• CPC Class Codes: A61K 39/4631 Chimeric Antigen Receptors [CAR]
• CPC Class Codes: A61K 39/464411 Immunoglobulin superfamily
• CPC Class Codes: A61K 39/464412 CD19 or B4
• CPC Class Codes: C07K 16/2803 against the immunoglobulin superfamily
• CPC Class Codes: C07K 2317/622 Single chain antibody (scFv)
• CPC Class Codes: C07K 2319/03 containing a transmembrane segment
• CPC Class Codes: C12N 2501/999 : Small molecules not provided for elsewhere
• CPC Class Codes: C12N 2510/00 : Genetically modified cells
• CPC Class Codes: C12N 2760/16134 : Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
• CPC Class Codes: C12N 5/0638 : Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]

Abstract

The invention relates, in part, to a method of treating a subject comprising administering to the subject a low, immune enhancing of a mTOR inhibitor and an immune effector cell engineered to express a CAR.

Claims

1. A method of treating a subject in need thereof comprising administering to the subject an mTOR inhibitor, wherein said mTOR inhibitor enhances an immune response of said subject, and wherein said subject has received, is receiving or is about to receive an immune effector cell engineered to express a CAR.

2. The method of claim 1, wherein the mTOR inhibitor is administered at a low, immune-enhancing dose.

6. The method of claim 1, wherein the CAR comprises an antigen binding domain, a transmembrane domain, and an intracellular signaling domain.

7. The method of claim 6, wherein the antigen binding domain binds a tumor marker, wherein the tumor marker is a solid tumor marker or a hematological cancer marker.

9. The method of claim 1, wherein:

i) the administration of the mTOR inhibitor is initiated prior to the administration of the immune effector cell engineered to express a CAR;

or

ii) the administration of the mTOR inhibitor is completed prior to the administration of the immune effector cell engineered to express a CAR.

11. The method of claim 1, wherein the administration of the mTOR inhibitor overlaps with the administration of the immune effector cell engineered to express a CAR.

12. The method of claim 1, wherein the immune effector cell engineered to express a CAR is administered after a sufficient time, or after sufficient dosing of the mTOR inhibitor, such that the level of PD1 negative immune effector cells, or the ratio of PD1 negative immune effector cells/PD1 positive immune effector cells, has been, at least transiently, increased.

13. The method of claim 1, wherein the immune effector cell to be engineered to express a CAR is harvested after a sufficient time, or after sufficient dosing of the mTOR inhibitor, such that the level of PD1 negative immune effector cells, or the ratio of PD1 negative immune effector cells/PD1 positive immune effector cells, in the subject or harvested from the subject has been, at least transiently, increased.

14. The method of claim 1, wherein the administration of the mTOR inhibitor continues after the subject has received the immune effector cell engineered to express a CAR.

15. The method of claim 1, wherein the mTOR inhibitor is:

i) an allosteric mTOR inhibitor;

ii) RAD001;

iii) rapamycin;

iv) a catalytic inhibitor;

v) a kinase inhibitor selective for mTOR;

or

vi) a kinase inhibitor selected from BEZ235 and CCG168.

21. The method of claim 1, comprising administering to the subject a plurality of mTOR inhibitors.

22. The method of claim 1, wherein the mTOR inhibitor is administered for an amount of time sufficient to decrease the proportion of PD-1 positive T cells, increase the proportion of PD-1 negative T cells, or increase the ratio of PD-1 negative T cells/PD-1 positive T cells, in the peripheral blood of the subject.

23. The method of claim 1, wherein the method comprises:

i) inhibiting a negative immune response mediated by the engagement of PD-1 with PD-L1 or PD-L2;

ii) increasing the number of T cells capable of proliferation;

or

iii) increasing the number of T cells capable of cytotoxic function, secreting cytokines, or activation.

26. The method of claim 1, wherein the mTOR inhibitor is administered prior to the administration of immune effector cells, for an amount of time sufficient for one or more of the following to occur:

i) a decrease in the number of PD-1 positive immune effector cells;

ii) an increase in the number of PD-1 negative immune effector cells;

iii) an increase in the ratio of PD-1 negative immune effector cells/PD-1 positive immune effector cells;

iv) an increase in the number of naive T cells;

v) an increase in the expression of one or more of the following markers;

CD62L^high, CD127^high, CD27⁺, and BCL2;

vi) a decrease in the expression of KLRG1;

or

vii) an increase in the number of memory T cell precursors.

27. The method of claim 1, wherein the mTOR inhibitor is administered at a dose that is associated with mTOR inhibition of:

i) at least 5 but no more than 90%;

ii) at least 10% but no more than 80%;

or

iii) at least 10% but no more than 40%.

30. The method of claim 1, wherein:

i) the mTOR inhibitor is RAD001 and is administered at a dose of 0.3 to 60, 1.5 to 30, 7.5 to 22.5, 9 to 18, or about 15 mgs;

ii) the mTOR inhibitor is an mTOR inhibitor other than RAD001, and the mTOR inhibitor is administered at a dose that is bioequivalent to a once per week, sustained release dosage form of 0.3 to 60, 1.5 to 30, 7.5 to 22.5, 9 to 18, or about 15 mgs of RAD001;

iii) the mTOR inhibitor is RAD001 and is administered at a dose of 0.005 to 1.5, 0.01 to 1.5, 0.1 to 1.5, 0.2 to 1.5, 0.3 to 1.5, 0.4 to 1.5, 0.5 to 1.5, 0.6 to 1.5, 0.7 to 1.5, 0.8 to 1.5, 1.0 to 1.5, 0.3 to 0.6, or about 0.5 mgs;

iv) the mTOR inhibitor is an mTOR inhibitor other than RAD001, and the mTOR inhibitor is administered at a dose that is bioequivalent to a once per day, immediate release dosage form of 0.005 to 1.5, 0.01 to 1.5, 0.1 to 1.5, 0.2 to 1.5, 0.3 to 1.5, 0.4 to 1.5, 0.5 to 1.5, 0.6 to 1.5, 0.7 to 1.5, 0.8 to 1.5, 1.0 to 1.5, 0.3 to 0.6, or about 0.5 mgs of RAD001;

v) the mTOR inhibitor is RAD001 and is administered at a dose that provides for a trough level of RAD001 in a range of between about 0.1 and 3 ng/ml, between 0.3 or less and 3 ng/ml, or between 0.3 or less and 1 ng/ml;

or

vi) the mTOR inhibitor is other than RAD001 and is administered at a dose that is bioequivalent to a dose of RAD001 that provides for a trough level of RAD001 in a range of between about 0.1 and 3 ng/ml, between 0.3 or less and 3 ng/ml, or between 0.3 or less and 1 ng/ml.

36. The method of claim 1, wherein the subject has cancer and the method comprises promoting the subject'"'"'s immune response to the cancer.

37. The method of claim 36, wherein:

i) a cell of the cancer expresses PD-L1 or PD-L2;

or

ii) a cell in the cancer microenvironment expresses PD-L1 or PD-L2.

39. The method of claim 36, wherein the cancer is:

i) a solid tumor;

ii) a haematological cancer;

iii) CLL;

or

iv) melanoma.

40. The method of claim 36, wherein the cancer is a hematological cancer and the antigen binding domain of the CAR targets CD19.

43. The method of claim 1, wherein the subject is a human.

44. The method of claim 1, wherein the immune effector cell is a T cell.

47. The method of claim 1, wherein the CAR comprises an antigen binding domain sequence disclosed in Table 3.

3. A method of making an immune effector cell, having disposed therein a nucleic acid encoding a CAR, comprising:

a) contacting an immune effector cell with an mTOR inhibitor; and

b) inserting a nucleic acid that encodes the CAR into the immune effector cell;

thereby making an immune effector cell, having disposed therein a nucleic acid encoding a CAR,

wherein said contacting of step a) occurs prior to, concurrently with, or after said inserting of step b);

and wherein the mTOR inhibitor causes one or more of the following to occur;

1a) an increase in the proportion of PD-1 negative immune effector cells;

1b) a decrease in the proportion of PD-1 positive immune effector cells;

1c) an increase in the ratio of PD-1 negative immune effector cells/PD-1 positive immune effector cells;

1d) an increase in the number of naï

ve T cells;

1e) an increase in the expression of one or more of the following markers;

CD62L^high, CD127^high, CD27⁺, and BCL2;

1f) a decrease in the expression of KLRG1;

or

1g) an increase in the number of memory T cell precursors.

4. The method of claim 3, wherein said contacting is ex vivo.

5. A method of making an immune effector cell, having disposed therein a nucleic acid encoding a CAR, comprising:

a) providing an immune effector cell made by;

i) administering to a subject an mTOR inhibitor for an amount of time sufficient for one or more of the following to occur;

1a) an increase in the proportion of PD-1 negative immune effector cells;

1b) a decrease in the proportion of PD-1 positive immune effector cells;

1c) an increase in the ratio of PD-1 negative immune effector cells/PD-1 positive immune effector cells;

1d) an increase in the number of naï

ve T cells;

1e) an increase in the expression of one or more of the following markers;

CD62L^high, CD127^high, CD27⁺, and BCL2;

1f) a decrease in the expression of KLRG1;

or

1g) an increase in the number of memory T cell precursors; and

(ii) collecting the immune effector cell from the subject; and

b) inserting a nucleic acid that encodes the CAR into the collected immune effector cell,

thereby making an immune effector cell, having disposed therein a nucleic acid encoding a CAR.

45. The method of claim 5, further comprising:

i) introducing the immune effector cell, having disposed therein a nucleic acid encoding a CAR, into a subject;

or

ii) evaluating the level of PD1 negative or PD1 positive immune effector cells in the subject or in T cells taken from the subject.

8. (canceled)

10. (canceled)

16-20. -20. (canceled)

24-25. -25. (canceled)

28-29. -29. (canceled)

31-35. -35. (canceled)

38. (canceled)

41-42. -42. (canceled)

46. (canceled)